Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on September 16, 2025. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol NAOV. The filing reports the entry into a material definitive agreement regarding a registered direct offering.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered direct offering of common stock and prefunded warrants.
- Shares Issued: 74,114 shares of Common Stock.
- Warrants Issued: Prefunded warrants to purchase up to 217,090 shares of Common Stock.
- Offering Price: $7.01 per share of Common Stock; $7.009 per Prefunded Warrant.
- Net Proceeds: Approximately $1.8 million after deducting placement agent fees and estimated offering expenses.
- Placement Agent Fee: 8.0% of gross proceeds paid to Palladium Capital Group, LLC.
- Use of Proceeds: General working capital, repayment of outstanding indebtedness, and/or redemption of outstanding preferred stock.
Note: This filing does not provide revenue, profit, cash flow, margin, or total debt figures for the company's operations.
Material Changes and Terms
The primary material change is the capital raise executed on September 16, 2025. Key terms include:
- Exercise Price: Prefunded warrants have an initial exercise price of $0.001 per share.
- Ownership Limitations: Holders (including affiliates) are restricted from exercising warrants if it would cause beneficial ownership to exceed 4.99% of outstanding shares, unless the holder elects to increase this limit to 9.99% with at least 61 days' prior notice.
- Legal Counsel: Haynes and Boone, LLP provided the legal opinion for the issuance.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use the net proceeds primarily for general working capital purposes, specifically highlighting the repayment of certain outstanding indebtedness and/or redemption of certain outstanding preferred stock.
Risks and Contingencies: The filing notes that representations and warranties in the Purchase Agreement were made solely for the benefit of the parties and may be subject to limitations. The text does not provide specific forward-looking guidance on future revenue or operational milestones beyond the immediate use of funds.
Investor Verification Checklist
- Verify the exact amount of "outstanding indebtedness" and "outstanding preferred stock" referenced for potential repayment or redemption.
- Confirm the total number of shares outstanding immediately prior to this offering to calculate the precise dilution impact of the 291,204 total potential shares (74,114 shares + 217,090 warrant shares).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions not detailed in the summary.
- Check subsequent filings for the actual redemption of preferred stock or debt repayment to confirm the allocation of the $1.8 million net proceeds.